{"groups":[{"description":"Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC\n\nPlacebo: Given IV","id":"FG000","title":"Arm I Gem+Doce+Placebo"},{"description":"Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nBevacizumab: Given IV\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC","id":"FG001","title":"Arm II Gem+Doce+Bev"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"53"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"53"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}